Osteosarcoma treatment granted rare pediatric disease designation
The U.S. Food and Drug Administration granted rare pediatric disease (RPD) designation for IVT-8086, a humanized monoclonal antibody (mAb), for the treatment of Osteosarcoma, according to a press release.
“The FDA’s Rare Pediatric Disease Designation of IVT-8086 for the treatment of osteosarcoma highlights the significant unmet medical needs for patients with this devastating and life-threatening disease. IVT-8086 has the potential to become the first FDA-approved therapy for individuals with osteosarcoma in over 30 years,” said Robert Ryan, PhD, Chief Executive Officer of Innova Therapeutics in a press release.
Read the full press release here.